The Value of 18F -FDG Metabolism Imaging in Evaluating the Response of Patients with Non-small Cell Lung Cancer in Stable Disease after Chemotherapy_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

CHENG Teng ¹ , SUN Lihua ¹ , WANGFeng ² , GU Wei ¹ , TAN Yan. ¹

Department of Respiratory Medicine, Nanjing Hospital Affilated to Nanjing Medical University ( Nanjing First Hospital) . Nanjing, Jiangsu, 210006, ChinaCorresponding Author: SUN Li-hua, E-mail: nfhsun@ sina. com;

Corresponding author：

Keywords：

Non-small cell lung cancer; Fluorodeoxyglucose; Metabolism imaging; Stable disease; Response evaluation

DOI：

DOI: 10 . 7507 /1671 -6205 . 20130111

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the value of 18 F-fluorodeoxyglucose ( 18 F-FDG) metabolism imaging in evaluating the response of patients with non-small cell lung cancer ( NSCLC) in stable disease
after chemotherapy.
Methods 28 patients with NSCLC in stable disease after chemotherapy admitted between September 2010 to September 2012 were retrospectively investigated. The reduction ratio of targetto-nontarget ratio ( T/N) before and after chemotherapy was calculated. The patients were followed up 3 to 12 months to measure progression-free survival ( PFS) . The correlation between the reduction ratio of T/N and PFS was analyzed. The patients were divided into a reduction group and a non-reduction group according to the difference of the reduction ratio of T/N and was compared the difference of the PFS.
Results The reduction ratio of T/N had positive correlation with PFS( Pearson r = 0. 668, P lt; 0. 01) . The PFS of the reduction group was longer than that in the non-reduction group ( 8. 0 ±2. 5 months vs. 5. 3 ±1. 2 months,P lt;0. 05) .
Conclusions The reduction ratio of T/N is positively correlated with PFS in NSCLC patients in stable disease after chemotherapy. It is possible to evaluate the efficacy of the treatment according to the reduction ratio of T/N.

Citation： CHENG Teng,SUN Lihua,WANGFeng,GU Wei,TAN Yan.. The Value of 18F -FDG Metabolism Imaging in Evaluating the Response of Patients with Non-small Cell Lung Cancer in Stable Disease after Chemotherapy. Chinese Journal of Respiratory and Critical Care Medicine, 2013, 12(5): 461-464. doi: DOI: 10 . 7507 /1671 -6205 . 20130111 Copy

1.	Steinert HC. PET and PET-CT of lung cancer. Methods Mol Biol,2011, 727: 33-51.
2.	赖灿, 杨建伟, 张江灵, 等. 探讨18 F-FDG SPECT-CT 在胃癌疗效评价中的价值. 肿瘤防治研究, 2010 , 37: 679-682.
3.	Festuccia C, Gravina GL, Millimaggi D, et al. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib inprostate cancer cells. Oncol Rep, 2007 , 18: 503-511.
4.	Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced nonsmall cell lung cancer. Lung Cancer, 2004, 44: 231-239.
5.	Behzadi A, Ung Y, Lowe V, et al. The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg, 2009, 52: 235-242.
6.	Kong FM, Frey KA, Quint LE, et al. A pilot study of [ 18 F] fluoro deoxy glucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer.J Clin Oncol, 2007, 25 : 3116-3123.
7.	Lee DH, Kim S, Lee H, et al. Early prediction of response to firstline therapy using integrated 18 F-FDG PET/ CT for patients with advanced metastatic non-small cell lung cancer. J Tborac Oncol,.
8.	Mudd SR, Voorbach MJ, Reuter DR, et al. FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib ( ABT-869 ) in a non-small cell lung cancerxenograft model. Cancer Chemother Pharmacol, 2012, 69: 1669 -1672.
9.	Takahashi R, Hirata H, Tachibana I, et al. Early [ 18 F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res, 2012, 18 : 220-228 .
10.	Nahmias C, Hannal WT, Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18 F-FDG PET/ CT. J Nucl Med, 2007, 48: 744-751 .
11.	Richard L, Heather J, Yvette K, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solidtumors. J Nucl Med, 2009 , 50: 122S-150S.
12.	Pottgen C, Levegrum S, Theegarten D, et al. Value of 18 F -fluoro-2-deoxy-D-glucose-positron emission tomography/ computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.Clin Cancer Res, 2006, 12: 97-106.
13.	, 4: 816-21.

1. Steinert HC. PET and PET-CT of lung cancer. Methods Mol Biol,2011, 727: 33-51.
2. 赖灿, 杨建伟, 张江灵, 等. 探讨18 F-FDG SPECT-CT 在胃癌疗效评价中的价值. 肿瘤防治研究, 2010 , 37: 679-682.
3. Festuccia C, Gravina GL, Millimaggi D, et al. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib inprostate cancer cells. Oncol Rep, 2007 , 18: 503-511.
4. Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced nonsmall cell lung cancer. Lung Cancer, 2004, 44: 231-239.
5. Behzadi A, Ung Y, Lowe V, et al. The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg, 2009, 52: 235-242.
6. Kong FM, Frey KA, Quint LE, et al. A pilot study of [ 18 F] fluoro deoxy glucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer.J Clin Oncol, 2007, 25 : 3116-3123.
7. Lee DH, Kim S, Lee H, et al. Early prediction of response to firstline therapy using integrated 18 F-FDG PET/ CT for patients with advanced metastatic non-small cell lung cancer. J Tborac Oncol,.
8. Mudd SR, Voorbach MJ, Reuter DR, et al. FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib ( ABT-869 ) in a non-small cell lung cancerxenograft model. Cancer Chemother Pharmacol, 2012, 69: 1669 -1672.
9. Takahashi R, Hirata H, Tachibana I, et al. Early [ 18 F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res, 2012, 18 : 220-228 .
10. Nahmias C, Hannal WT, Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18 F-FDG PET/ CT. J Nucl Med, 2007, 48: 744-751 .
11. Richard L, Heather J, Yvette K, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solidtumors. J Nucl Med, 2009 , 50: 122S-150S.
12. Pottgen C, Levegrum S, Theegarten D, et al. Value of 18 F -fluoro-2-deoxy-D-glucose-positron emission tomography/ computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.Clin Cancer Res, 2006, 12: 97-106.
13. , 4: 816-21.

Chinese Journal of Respiratory and Critical Care Medicine

The Value of 18F -FDG Metabolism Imaging in Evaluating the Response of Patients with Non-small Cell Lung Cancer in Stable Disease after Chemotherapy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content